Dr. Maddocks is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-8619Fax+1 614-293-6420
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
- University of South Dakota, Sanford School of MedicineClass of 2005
Certifications & Licensure
- OH State Medical License 2008 - 2026
- MN State Medical License 2006 - 2008
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2011 Dec 07
- IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Start of enrollment: 2012 Jan 01
- PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Start of enrollment: 2012 May 21
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsOSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cellsTa-Ming Liu, Yonghua Ling, Jennifer A. Woyach, Kyle A. Beckwith, Yuh Ying Yeh
Blood. 2015-01-08 - 41 citationsPKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLLDalia El-Gamal, Katie L. Williams, Taylor D. LaFollette, Matthew Cannon, James S. Blachly
Blood. 2014-08-28 - 168 citationsAuranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic LeukemiaWarren Fiskus, Nakhle S. Saba, Min Shen, Mondana H. Ghias, Jinyun Liu
Cancer Research. 2014-05-01
Journal Articles
- Update on Mantle Cell LymphomaKami Maddocks, MD, Blood
Abstracts/Posters
- T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell LymphomaKami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin LymphomaKami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patie...2019 ASCO Annual Meeting - 6/1/2019
- Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- The Ohio State Kicks off Blood Battle Against University of MichiganOctober 22nd, 2024
- Comorbidities and Role of R-CHOP in DLBCLFebruary 7th, 2020
- Potential Ibrutinib Resistance Mechanisms Identified in CLLMarch 20th, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: